Oppenheimer analyst Hartaj Singh reiterated a Perform rating on Sarepta Therapeutics (NASDAQ: SRPT) after reporting quarterly sales of ~$122.6M (~23 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE